Author: Chiricozzi, Andrea; Talamonti, Marina; De Simone, Clara; Galluzzo, Marco; Gori, Niccolò; Fabbrocini, Gabriella; Marzano, Angelo Valerio; Girolomoni, Giampiero; Offidani, Annamaria; Rossi, Maria Teresa; Bianchi, Luca; Cristaudo, Antonio; Fierro, Maria Teresa; Stingeni, Luca; Pellacani, Giovanni; Argenziano, Giuseppe; Patrizi, Annalisa; Pigatto, Paolo; Romanelli, Marco; Savoia, Paola; Rubegni, Pietro; Foti, Caterina; Milanesi, Nicola; Belloni Fortina, Anna; Bongiorno, Maria Rita; Grieco, Teresa; Di Nuzzo, Sergio; Fargnoli, Maria Concetta; Carugno, Andrea; Motolese, Alberico; Rongioletti, Franco; Amerio, Paolo; Balestri, Riccardo; Potenza, Concetta; Micali, Giuseppe; Patruno, Cataldo; Zalaudek, Iris; Lombardo, Maurizio; Feliciani, Claudio; Di Nardo, Lucia; Guarneri, Fabrizio; Peris, Ketty
Title: Management of patients with atopic dermatitis undergoing systemic therapy during COVIDâ€19 pandemic in Italy: Data from the DAâ€COVIDâ€19 registry Cord-id: ynadltcu Document date: 2021_3_9
ID: ynadltcu
Snippet: BACKGROUND: Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVIDâ€19) pandemic. METHODS: A national registry, named DAâ€COVIDâ€19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVIDâ€19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or photothe
Document: BACKGROUND: Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVIDâ€19) pandemic. METHODS: A national registry, named DAâ€COVIDâ€19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVIDâ€19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVIDâ€19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician†and patientâ€reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity. RESULTS: A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARSâ€CoVâ€2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARSâ€CoVâ€2 infection; 3 of them (0.2%) were hospitalized but no cases of COVIDâ€related death occurred. CONCLUSIONS: Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumabâ€treated patients.
Search related documents:
Co phrase search for related documents- ad improvement and ad severity: 1
Co phrase search for related documents, hyperlinks ordered by date